Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with concurrent chemoradiotherapy in pediatric DIPG
CTR20201137Phase 2Completed
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in diffuse intrinsic pontine glioma (DIPG), sponsored by Biotech Pharmaceutical Co., Ltd.. Started Sep 2020; status: completed.
02
Drugs
nimotuzumab
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on CTR20201137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201137.